Literature DB >> 3355248

Anticardiolipin antibodies, livedo reticularis, and major cerebrovascular and renal disease in systemic lupus erythematosus.

N J McHugh1, J Maymo, R P Skinner, I James, P J Maddison.   

Abstract

Increased levels of IgG anticardiolipin antibodies (ACA) were found in 23 of 98 patients (23%) with systemic lupus erythematosus. Increased levels of IgM ACA were found less frequently (5%). All four patients with major cerebrovascular events had increased IgG ACA, including the two with highest levels, both of whom were men. Six of nine patients with livedo reticularis had increased IgG ACA. In turn, this clinical feature was associated with cerebrovascular disease in two and renal disease in another six. IgG ACA were not associated with other thromboembolic events, thrombocytopenia, serum IgG, or autoantibodies to Ro(SSA), La(SSB), U1RNP, Sm, or double or single stranded DNA.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3355248      PMCID: PMC1003462          DOI: 10.1136/ard.47.2.110

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  17 in total

1.  CEREBRO-VASCULAR LESIONS AND LIVEDO RETICULARIS.

Authors:  I B SNEDDON
Journal:  Br J Dermatol       Date:  1965-04       Impact factor: 9.302

Review 2.  The natural history of systemic lupus erythematosus by prospective analysis.

Authors:  D Estes; C L Christian
Journal:  Medicine (Baltimore)       Date:  1971-03       Impact factor: 1.889

3.  Anticardiolipin antibodies and lupus anticoagulant.

Authors:  E N Harris; S Loizou; H Englert; G Derue; J K Chan; A E Gharavi; G R Hughes
Journal:  Lancet       Date:  1984-11-10       Impact factor: 79.321

4.  Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955--1977.

Authors:  S G Ellis; M A Verity
Journal:  Semin Arthritis Rheum       Date:  1979-02       Impact factor: 5.532

5.  Lupus anticoagulant in pregnancy.

Authors:  W F Lubbe; W S Butler; S J Palmer; G C Liggins
Journal:  Br J Obstet Gynaecol       Date:  1984-04

6.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

7.  Cerebrovascular lesions and livedo reticularis (Sneddon's syndrome)--a progressive cerebrovascular disorder?

Authors:  E Rumpl; J Neuhofer; A Pallua; J Willeit; G Vogl; G Stampfel; T Platz
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

8.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

9.  Systemic lupus erythematosus. A prospective analysis.

Authors:  R Grigor; J Edmonds; R Lewkonia; B Bresnihan; G R Hughes
Journal:  Ann Rheum Dis       Date:  1978-04       Impact factor: 19.103

10.  Neuropsychiatric lupus.

Authors:  T Abel; D D Gladman; M B Urowitz
Journal:  J Rheumatol       Date:  1980 May-Jun       Impact factor: 4.666

View more
  11 in total

1.  Lupus anticoagulant: clinical significance in anticardiolipin positive patients with systemic lupus erythematosus.

Authors:  N J McHugh; D A Moye; I E James; M Sampson; P J Maddison
Journal:  Ann Rheum Dis       Date:  1991-08       Impact factor: 19.103

2.  Antiphospholipid antibodies and Mycoplasma pneumoniae infection.

Authors:  N Snowden; P B Wilson; M Longson; R S Pumphrey
Journal:  Postgrad Med J       Date:  1990-05       Impact factor: 2.401

3.  Anticardiolipin antibodies, livedo reticularis, and cerebrovascular accidents in SLE.

Authors:  E Baguley; R A Asherson; G R Hughes
Journal:  Ann Rheum Dis       Date:  1988-08       Impact factor: 19.103

4.  Anticardiolipin antibodies and occlusive vascular disease of the eye: prospective study.

Authors:  C D Kalogeropoulos; P Spyrou; M I Stefaniotou; E E Tsironi; A A Drosos; K G Psilas
Journal:  Doc Ophthalmol       Date:  1998       Impact factor: 2.379

5.  Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the 'primary' antiphospholipid syndrome.

Authors:  R A Asherson; P Merry; J F Acheson; E N Harris; G R Hughes
Journal:  Ann Rheum Dis       Date:  1989-05       Impact factor: 19.103

6.  Clinical importance of persistence of anticardiolipin antibodies in systemic lupus erythematosus.

Authors:  Y Ishii; K Nagasawa; T Mayumi; Y Niho
Journal:  Ann Rheum Dis       Date:  1990-06       Impact factor: 19.103

Review 7.  Livedo reticularis as a criterion for antiphospholipid syndrome.

Authors:  E Toubi; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

8.  Association of antiphospholipid antibodies with systemic lupus erythematosus in a child presenting with chorea: a case report.

Authors:  N Besbas; I Damarguc; S Ozen; S Aysun; U Saatci
Journal:  Eur J Pediatr       Date:  1994-12       Impact factor: 3.183

Review 9.  Diagnosis and pathogenesis of CNS lupus.

Authors:  A P van Dam
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

10.  IGM-containing immune complexes and antiphospholipid antibodies in patients with Sneddon's syndrome.

Authors:  E Schulze-Lohoff; F Krapf; L Bleil; G R Burmester; K Kölble; H G Nüsslein; W Rödl; J R Kalden
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.